This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Intranasal Insulin
Off-label use of regular human insulin (Humulin R, NovoLog) delivered via specialized intranasal atomizer to reach brain insulin receptors…
Aliases (5)
Overview
What is Intranasal Insulin?
Intranasal insulin is regular human insulin delivered as a nasal spray to reach the central nervous system via the olfactory and trigeminal pathways with minimal systemic absorption. It is investigational for cognitive disorders and metabolic conditions.
Key Benefits
Improves memory and executive function in healthy adults and Alzheimer's/MCI patients, enhances mood and arousal acutely, supports central insulin signaling without peripheral hypoglycemia, and may slow cognitive decline in early AD.
Mechanism of Action
Bypasses the blood-brain barrier via olfactory and trigeminal nerve pathways to activate brain insulin receptors in the hippocampus, hypothalamus, and prefrontal cortex, enhancing glucose metabolism, synaptic plasticity, and PI3K/Akt signaling.
Pharmacokinetics
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Cholinergic precursor complements insulin's effect on synaptic plasticity. Both upregulate hippocampal function via different pathways. Already in the user's…
Membrane fluidity supports insulin receptor function; well-established neurotrophic synergy. Already in the user's V stack (2 g DHA/day).
Hippocampal-targeted Mg supports NMDA function; complementary to insulin's plasticity signaling. Already in the user's V stack.
Different mechanism (BDNF/NGF transcriptional upregulation vs insulin receptor signaling). Theoretically synergistic for hippocampal support; no published co…
Both target neurotrophic / synaptic plasticity pathways. Theoretical synergy.
Different receptor system but similar nose-to-brain delivery considerations; some users alternate or stack for separate effects (insulin = memory, oxytocin =…
additive glycemic effect. Not relevant for users in this archetype.
practical concern: only one nose-to-brain protocol can target the olfactory cleft cleanly per session. If stacking with Semax/Adamax, alternate nostrils OR a…
alter mucosal physiology, may impair olfactory deposition. Avoid concurrent use during IN insulin protocol.
Quality Indicators
Sterile pre-filled spray
Spray bottles should be sealed, sterile, and labeled with concentration.
Refrigeration required
Most intranasal peptides require fridge storage; a warm bottle suggests degraded peptide.
Cloudy or discolored liquid
Cloudiness or color change indicates degradation or contamination.
What to Expect
- Day 1-7Injection / administration protocol established. Tolerability check.
- Week 2-4Early onset of effect — subtle in most users, noticeable in responders.
- Week 4-8Peak benefit window for most peptide cycles.
- Week 8+Cycle decision point: continue, taper, or break.
Side Effects & Safety 5
Side Effects
- 1Mild nasal irritation — burning, runny nose, mild congestion. Most common adverse event in trials. Usually mild and self-resolving.
- 2Mild rhinitis — chronic users may develop low-grade rhinitis with sustained daily use.
- 3Transient mild blood glucose drop at 15-30 min post-dose (<10 mg/dL typically). Clinically insignificant in non-diabetic users. Concern: in a 20yo with normal glucose regulation, this is a non-issue. In someone with reactive hypoglycemia tendency, monitor.
- 4Mild headache — first few doses, usually fades.
- 5Nasopharyngitis / mild sore throat if technique is wrong (peptide drains down throat).
When to Stop
- Allergy to insulin or excipients — rare but documented. Insulin formulations contain meta-cresol or phenol as preservatives, which can rarely cause local mucosal reactions.
- Theoretical risk: nasal mucosal atrophy with chronic high-dose use — not documented at therapeutic IN insulin doses but is a known risk class for chronic intranasal protein/peptide therapy generally.
- Theoretical risk: tachyphylaxis at hypothalamic insulin signaling — chronic IN insulin in healthy users could theoretically downregulate hypothalamic insulin receptors. Not documented in trial duration (1 year max). Long-term (>1 year) safety in healthy users is unstudied.
- First 1-2 weeks: monitor for nasal irritation pattern, headache, any glycemic awareness symptoms.
- First 4-8 weeks: assess subjective signal; if zero detectable benefit, reconsider continuation given cost + complexity.
- Hypoglycemia (clinically meaningful)
- Weight changes (no consistent signal in trials, though Hallschmid mild appetite reduction)
- Cardiovascular effects
- Endocrine disruption
- Dependence / withdrawal
References
Craft 2012 — Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment, Arch Neurol
Pivotal positive Phase 2 trial, n=104, 4 months
View StudyCraft 2017 — Effects of regular and long-acting insulin on cognition and Alzheimer's biomarkers, J Alzheimers Dis
Comparison of insulin types
View StudyCraft 2020 SNIFF — A Phase II/III randomized clinical trial of intranasal insulin for amnestic MCI/AD, JAMA Neurol
The SNIFF trial; missed primary endpoint with documented device-change confound
View StudySNIFF supplementary device-change discussion
ClinicalTrials.gov registry for SNIFF including device protocol amendments
View StudyBenedict 2004 — Intranasal insulin improves memory in humans, Psychoneuroendocrinology
First healthy-adult cognitive benefit demonstration
View StudyBenedict 2007 — Intranasal insulin improves memory in humans: superiority of insulin aspart, Neuropsychopharmacology
Replication + analog comparison
View StudyHallschmid 2008 — Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man, Physiol Behav
Food-reward modulation review
View StudyHallschmid 2012 — Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women
Reger 2008 — Intranasal insulin improves cognition and modulates β-amyloid in early AD, Neurology
APOE4 interaction signal
View StudyReger 2006 — Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype, Neurobiol Aging
Born 2002 — Sniffing neuropeptides: a transnasal approach to the human brain, Nat Neurosci
Foundational nose-to-brain delivery paper
View StudyLochhead Thorne 2012 — Intranasal delivery of biologics to the central nervous system, Adv Drug Deliv Rev
Comprehensive nose-to-brain transport review
View StudySchmid Hallschmid 2018 — Hypothalamic insulin sensitivity in lean and obese men, Diabetologia
Kullmann 2020 — Brain insulin resistance at the crossroads of metabolic and cognitive disorders, Physiol Rev
Comprehensive brain insulin signaling review
View StudyAvgerinos 2018 — Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: meta-analysis, J Neurol
Brünner 2015 — Effects of intranasal insulin on cognition in MCI and the moderating role of cortisol, Psychoneuroendocrinology
Aptar Pharma OptiMist intranasal device platform
Research-grade nasal delivery
View StudyBredesen ReCODE protocol IN insulin discussion
Functional medicine clinical use context
View StudyWADA Prohibited List 2026 — Section S4.5 hormone and metabolic modulators (insulin)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.